Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGAV | P06756 | 3/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834913 | 0.87 | PIN1 (0.42) | PIN1PDE10AITGB1ITGA5KDM4E | |
| SCHEMBL3829591 | 0.80 | ITGA4 (0.49) | ITGB1ITGA5 | |
| SCHEMBL3835224 | 0.79 | ITGB1 (0.53) | ITGAVITGB1ITGA5 | |
| SCHEMBL3836591 | 0.79 | ITGB1 (0.40) | PIN1ITGAVITGB1ITGA5 | |
| SCHEMBL3831720 | 0.78 | ITGB1 (0.48) | ITGB1ITGA5 | |
| SCHEMBL3834877 | 0.75 | HRH4 (0.45) | PDE10ADRD3 | |
| SCHEMBL4208543 | 0.73 | ITGB1 (0.43) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4221351 | 0.71 | ITGB1 (0.45) | PIN1PDE10AITGB3ITGAVITGB1 | |
| SCHEMBL3837141 | 0.71 | ITGA4 (0.51) | ITGB1ITGA5 | |
| SCHEMBL3831658 | 0.70 | L3MBTL1 (0.49) | ITGB3ITGAVITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | claimed |
| EP-2091916-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | AstraZeneca AB (SE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | PIN1 3139/4885HTR2B 759/4885PDE10A 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.